Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Howard

Internal Medicine Owensboro, KY Medical Doctor

NPI 1356319354 CMS profile 242595

2200 E Parrish Ave, Bld B, Ste. 202, Owensboro, KY 42303

Open in the dashboard

General payments

$9,321

665 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Howard of Owensboro, KY is reported in the CMS Open Payments database as having received $9,321 across 665 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2024 General $490 32
2023 General $1,240 81
2022 General $2,127 141
2021 General $2,082 146
2020 General $1,688 123
2019 General $1,677 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Howard
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Howard were reported at $17. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Howard Internal Medicine median Middle half National median
2019 $1,677 $159 $48–$570 $163
2020 $1,688 $119 $33–$402 $114
2021 $2,082 $135 $37–$521 $132
2022 $2,127 $141 $42–$496 $149
2023 $1,240 $149 $45–$519 $160
2024 $490 $154 $47–$537 $164
2025 $17 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,723 119 payments
  2. Novo Nordisk Inc $931 67 payments
  3. Amarin Pharma Inc. $789 85 payments
  4. AstraZeneca Pharmaceuticals LP $689 39 payments
  5. Lilly USA, LLC $685 45 payments
  6. AbbVie, Inc. $669 53 payments
  7. Horizon Therapeutics plc $484 36 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $361 24 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $316 19 payments
  10. Kowa Pharmaceuticals America, Inc. $253 17 payments
  11. Other $2,421 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,991 627 payments
  2. Education $312 37 payments
  3. Gift $18 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $745 54 payments
  2. AIMOVIG $709 50 payments
  3. Prolia $689 50 payments
  4. RYBELSUS $645 47 payments
  5. EVENITY $626 46 payments
  6. Repatha $605 38 payments
  7. Vascepa $493 44 payments
  8. FARXIGA $475 24 payments
  9. Otezla $417 26 payments
  10. Kerendia $361 24 payments
  11. Other $6,336 464 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

7,021

Median for Internal Medicine: 777

Drug cost

$269,671

Median for Internal Medicine: $73,373

Branded share of claims

12.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 51 $72,455
Ozempic Semaglutide Brand 43 $48,943
Farxiga Dapagliflozin Propanediol Brand 15 $24,765
Januvia Sitagliptin Phosphate Brand 11 $18,009
Eliquis Apixaban Brand 22 $11,971
Synthroid Levothyroxine Sodium Brand 118 $10,636
Rosuvastatin Calcium Generic 774 $7,828
Premarin Estrogens, Conjugated Brand 15 $4,586
Ezetimibe Generic 203 $4,198
Montelukast Sodium Generic 370 $4,098

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$204,730

Of which drugs: $53,115

Medicare patients

468

Average age 76

Services billed

6,914

219 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 43%
Diabetes 32%
Osteoporosis 27%
Atrial fibrillation 23%
Chronic kidney disease 23%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 40 2,400 $47,254
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 56 190 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $53
$53 51 —
RYBELSUS
  • Novo Nordisk Inc $47
$47 — —
Ozempic
  • Novo Nordisk Inc $47
$47 43 —
MOUNJARO
  • Lilly USA, LLC $33
$33 — —
Wegovy
  • Novo Nordisk Inc $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

665 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record